SAB Biotherapeutics, Inc. 8-K

What Happened

• On July 7, 2026, SAB Biotherapeutics, Inc. (SAB BIO) issued a press release disclosing that Breakthrough T1D awarded a grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida, to support PRISE-hATG, a clinical study evaluating SAB-142.
• PRISE-hATG will evaluate SAB-142 in patients with Stage 3 type 1 diabetes (diagnosed when insulin is required) who are 100 days to two years from diagnosis. The press release was furnished as Exhibit 99.1 to the Form 8-K (Item 7.01 Regulation FD Disclosure).

Key Details

• Date filed: July 7, 2026 (Form 8-K, Item 7.01 and Exhibit 99.1).
• Grant recipient: Michael J. Haller, M.D., University of Florida.
• Study: PRISE-hATG testing SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis.
• Financial terms of the grant or any funding amounts were not disclosed in the filing.

Why It Matters

• This grant represents external support and validation from a major T1D advocacy/research organization, which can help advance SAB BIO’s SAB-142 clinical program without immediate disclosed company expense.
• Progress on PRISE-hATG is a pipeline development item investors should track—advancement in Stage 3 T1D studies affects clinical risk and future value potential for SAB BIO’s therapeutic candidate.
• The filing contains no financial results or operational changes; it is a disclosure of a clinical funding/partnership development rather than a material financial event.